Why no announcements, page-56

If WP states in the recent company announcement that new supportive capital will not be dilutive that suggests to me that he will do a TAVR deal which would involve the valve tech independently and not involve the company as such i.e. sell 60% of the TAVR for $35m which would keep us afloat and reduce our future TAVR ongoing costs without dilution. In other words sell a fraction of the company to keep the rest afloat.
Either that or he has a buyer for the infusion business which he will announce soon. I cannot help thinking that the TAVR interest is very costly to keep progressing. IF we sold 75% of this business we might reduce our costs by 50% and become profitable? We could still supply the Adapt material for the TAVR and the 4C valves as well as retaining a percentage interest in the TAVR story. At least we would survive and thrive with a P/E of 40 or more.